Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLPLDC Vaccine + CPI in Metastatic Melanoma
NCT02678741Phase 2Completed
- Sponsor
- Elios Therapeutics
- Start
- Feb 2016
- Primary completion
- Oct 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TLPLDC vaccine in melanoma, sponsored by Elios Therapeutics. Started Feb 2016; status: completed.
02
Drugs
TLPLDC vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02678741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678741.